Business
Bruker Launches CE-IVD Quantitative Coronavirus Mid-Plex PCR Assay with Mutation Detection for Routine Variant Differentiation
FluoroType® SARS-CoV-2 varID Q is a novel LiquidArray® mid-plex PCR panel Detection of selected SARS-CoV-2 mutations enables differentiation of major viral
About this update from Bruker Corporation
[{"type":"text","content":"\n\nFluoroType® SARS-CoV-2 varID Q is a novel LiquidArray® mid-plex PCR panel \n\n\nDetection of selected SARS-CoV-2 mutations enables differentiation of major viral variants, or strains, without the costs and delays of selective NGS for variant epidemiology \n\n\nQuantification of viral load provides indication of infectivity and of stage of COVID infection\n\n\nValidated with nasopharyngeal swabs and oropharyngeal swabs for highest sensitivity \n\n\n NEHREN, Germany--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced the launch of the FluoroType SARS-CoV-2 varID Q assay – a quantitative LiquidArray® mid-plex PCR panel. This novel assay panel also detects several important mutations to enable laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The very sensitive FluoroType SARS-CoV-2 varID Q diagnostic test detects the SARS-CoV-2 virus using three independent gene targets for high assay robustness, even in case of future additional mutations. The assay achieved a sensitivity of 98% and a specificity of 100% during its clinical performance evaluation study.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005087/en/FluoroType SARS-CoV-2 varID Q test kit (Photo: Business Wire)\nThe CE-IVD marked FluoroType SARS-CoV-2 varID Q assay simultaneously detects and differentiates four major virus mutations. Their combinations determine multiple major variants, such as the original Wuhan strain, as well as variants that have emerged in the UK (B.1.1.7), in Nigeria (B.1.525), in South Africa (B.1.351), in Brazil (P.1), and in Denmark (B.1.1.298). While this test does not differentiate the new Indian strains (e.g., B.1.617), they are reported reliably as SARS-CoV-2.\n\nMoreover, the FluoroType SARS-CoV-2 varID Q assay now also offers quantification of the viral load in the sample in standardized International Units per milliliter (IU/ml), in accordance with WHO standards1. Quantitative PCR results may provide insights into whether the COVID patient is likely to be infectious, or whether she/he may already be in a later COVID stage with low viral loads.\n\nSensitive and robust detection, mutation differentiation and quantification of viral load are all done simultaneously in a single PCR tube and a single ...